Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward

Phase 2negativeNegative

AI Analysis

Summary

Acadia Pharmaceuticals' anti-psychosis candidate failed to meet the primary endpoint in a Phase 2 trial for Alzheimer's disease, but the company intends to continue development in both Alzheimer's psychosis and Lewy body dementia indications.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Missed primary endpoint

Importance:6/10

Sentiment:

-0.60

Phase 2failed trialAlzheimer's diseasepsychosisLewy body dementia

Related Companies

$ACAD

Read the original article

Published by BioSpace on September 24, 2026 2:25 PM

Read Original